Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Dexcom, Inc.
EIR
•Dexcom, Inc.•March 29, 2016

Dexcom, Inc. – FDA EIR, Mar 29, 2016

Record Details

An FDA Post-Market Surveillance inspection of Dexcom Inc., a manufacturer of continuous blood glucose monitoring systems in San Diego, CA, was conducted from March 22-29, 2016. The inspection, carried out under Compliance Program Guidance Manual 7383.001, focused on post-market activities for medical devices, specifically Dexcom's G4 Platinum systems and components supplied for the Animas Vibe System. It encompassed a review of the company's Quality System Inspection Technique (QSIT) subsystems, including Management Review, Corrective and Preventive Actions (CAPA), Design Controls, and Production and Process Controls. The primary observation noted on an FDA Form 483 was the company’s failure to fully implement written Medical Device Reporting (MDR) procedures. While Dexcom Inc. updated its MDR Reporting procedure in November 2015 to classify a specific 'failed error' complaint code as a reportable malfunction, the firm did not perform a comprehensive retrospective review of approximately 565 prior complaints received with this now-reportable code between November 2014 and June 2015. Despite claims that none of these complaints resulted in serious injury, the revised procedure mandated reporting of all such malfunctions. Consequently, Dexcom Inc. is required to rectify this deficiency, ensuring their MDR procedures are rigorously followed, including conducting retrospective analyses of complaints when reporting classifications are updated, to comply with regulatory obligations.

Company
Dexcom, Inc.
Inspection date
March 29, 2016
Product type
devices
Office
Center for Devices and Radiological Health
People
  • Shaquenta Perkins
  • Kevin R. Sayer (recipient)
  • Duane Durbin (company_representative)
  • Trent Davalos (company_representative)
  • David J. Carner (company_representative)
View Company Profile

ID · 8186d170-c81e-475a-8f4c-33e01a4ec90a

Violation Codes4
21 CFR 81421 CFR 820.3021 CFR 80321 CFR 803.17

Full citation text and observation details available on the Dashboard.

Other documents for Dexcom, Inc.
  • WARNING_LETTER - 2024-11-07November 7, 2024
  • 483 - 2024-11-07November 7, 2024
  • 483 - 2021-09-17September 17, 2021
  • EIR - 2018-02-16February 16, 2018
  • EIR - 2015-04-21April 21, 2015

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Dexcom, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.